Walleye Capital LLC Purchases Shares of 3,268,012 Allogene Therapeutics, Inc. $ALLO

Walleye Capital LLC purchased a new position in shares of Allogene Therapeutics, Inc. (NASDAQ:ALLO) during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 3,268,012 shares of the company’s stock, valued at approximately $6,797,000.

Several other hedge funds have also made changes to their positions in the business. AQR Capital Management LLC purchased a new stake in shares of Allogene Therapeutics in the first quarter valued at $85,000. Goldman Sachs Group Inc. lifted its position in Allogene Therapeutics by 177.9% during the first quarter. Goldman Sachs Group Inc. now owns 5,853,974 shares of the company’s stock worth $8,547,000 after buying an additional 3,747,397 shares during the period. Jane Street Group LLC boosted its stake in Allogene Therapeutics by 578.7% in the 1st quarter. Jane Street Group LLC now owns 1,116,681 shares of the company’s stock worth $1,630,000 after buying an additional 952,158 shares during the last quarter. Geode Capital Management LLC boosted its stake in Allogene Therapeutics by 13.0% in the 2nd quarter. Geode Capital Management LLC now owns 3,794,827 shares of the company’s stock worth $4,289,000 after buying an additional 435,389 shares during the last quarter. Finally, Rhumbline Advisers boosted its stake in Allogene Therapeutics by 14.0% in the 2nd quarter. Rhumbline Advisers now owns 209,336 shares of the company’s stock worth $237,000 after buying an additional 25,628 shares during the last quarter. Institutional investors and hedge funds own 83.63% of the company’s stock.

Allogene Therapeutics Stock Up 3.5%

Shares of ALLO opened at $2.05 on Friday. The firm has a market cap of $707.57 million, a PE ratio of -3.06 and a beta of 0.48. The company’s fifty day moving average is $1.96 and its two-hundred day moving average is $2.12. Allogene Therapeutics, Inc. has a fifty-two week low of $1.03 and a fifty-two week high of $4.46.

Allogene Therapeutics (NASDAQ:ALLO) last announced its quarterly earnings data on Wednesday, August 12th. The company reported ($0.13) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.17) by $0.04. The company had revenue of $4.64 million for the quarter, compared to analysts’ expectations of $0.00 million. As a group, equities research analysts anticipate that Allogene Therapeutics, Inc. will post -0.7 earnings per share for the current year.

Wall Street Analyst Weigh In

Separately, Weiss Ratings downgraded shares of Allogene Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Wednesday. One investment analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Allogene Therapeutics presently has a consensus rating of “Moderate Buy” and an average price target of $8.52.

Allogene Therapeutics Profile

Allogene Therapeutics is a clinical-stage biotechnology company focused on developing allogeneic, or “off-the-shelf,” chimeric antigen receptor T-cell (CAR T) therapies to treat a range of hematologic malignancies and solid tumors. The company leverages gene-editing technologies to generate universally compatible engineered T cells, aiming to overcome the limitations of patient-specific CAR T approaches such as manufacturing delays, variable product quality and treatment resistance.

The company’s pipeline includes multiple allogeneic CAR T candidates targeting key antigens in blood cancers.